1. The Company is primarily engaged in a business of manufacture and sale of Medical Devices and, hence, there is no reportable segment as per Accounting Standard-17 issued by ICAI.

2.(a) Other expenditure includes Exchange fluctuation loss of Rs 313.43 Lacs for the quarter and Rs 973.82 Lacs up to the quarter. (Exchange Fluctuation gain of Rs 97.65 Lacs for the quarter and Rs 592.37 Lacs up to the quarter for the previous financial year is included in other Income).

b. The Company has opted for accounting the exchange difference of long term foreign currency monetary items in line with Companies (Accounting Standards) amendment Rules 2009 with AS-11 notified by Government of India on March 31, 2009. Accordingly the effect of exchange difference on long term foreign currency monetary items of the Company related to the acquisition of depreciable capital assets is adjusted to the cost of the asset amounting to Rs 29.86 and as a result depreciation for the year is higher by 3.09 lacs. In other cases, same are accumulated in a Foreign Currency Monetary Translation Difference Account amounting to Rs (-) 24.23 lacs to be mortised in the next two years.

3. The Board of Directors have recommended a dividend of Rs 2.50 per equity share (previous year Rs 2.50 per equity share) of Rs 10 each subject to approval of the shareholders.

4. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on May 30, 2009.

5. The figures for the corresponding periods have been restated, wherever necessary, to make them comparable.

Himanshu Baid
Managing Director